Key points are not available for this paper at this time.
When the Food and Drug Administration (FDA) turned down Lykos Therapeutics' application for its MDMA drug to treat post‐traumatic stress disorder (PTSD) (see ADAW https://onlinelibrary.wiley.com/doi/10.1002/adaw.34219 ), the company seemed optimistic about the future. A couple weeks later, reality apparently set in. The company, which had been known as the for‐profit arm of MAPS, reorganized.
Alison Knopf (Fri,) studied this question.